Please note: Work is currently underway to update content available on this site.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Director Letters (formerly MELs/CELs/HDLs etc) are currently being reviewed to ensure it is clear which publications are current, superseded or obsolete.
Publication #3155
Reference
Drug alert
Name
Urgent: Sibutramine: suspension of marketing authorisations as risks outweigh benefits
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
SECURITY
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
RISKS
CARDIOVASCULAR DISEASES
Description
A European Medicines Agency (EMA) a review of the obesity medicine Sibutramine (Reductil) has found that the cardiovascular risks of Sibutramine outweigh its benefits. The EMA's Committee for Medicinal Products for Human Use has recommended suspension of the marketing authorisation for this medicine across the European Union.
Contact Name
Bill Scott
Contact Email
Contact Address
Pharmacy Division, Primary and Community Care Directorate, St Andrew’s House, Regent Road, Edinburgh, EH1 3DG.
Contact Phone
Created
2010-01-21 00:00:00
Click to go back to homepage